Targeted drug cobimetinib tested for rare immune cell cancers
Disease control
Recruiting now
This phase 2 study tests the drug cobimetinib in children and adults with Langerhans cell histiocytosis and related disorders that have come back or not responded to standard treatment. Cobimetinib blocks a growth signal that goes haywire in these diseases. The study will enroll …
Phase: PHASE2 • Sponsor: Carl Allen • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC